上海宝济药业股份有限公司（“宝济药业-B”，02659）于2026年3月4日发布截至2026年2月28日的股份变动月报表。公告显示，公司本月并无新增股份发行、购回或注销活动，股本保持稳定。
公司注册股本方面，截至报告期末，普通股H股法定/注册股本仍为154,327,250股，面值每股人民币0.2元；普通股内资股法定/注册股本为171,654,215股，面值同为人民币0.2元。两项合计的注册股本约为人民币65,196,293元，与上月持平。
已发行股份方面，H股与内资股本期均无变动，分别维持在154,327,250股和171,654,215股。公司在公告中确认目前H股的公众持股量符合香港联交所的相关规定。同时，本期未有任何期权、权证、可换股票据或其他形式的股份增减，并无库藏股发生变化。
公告同时提及，公司已遵守香港联交所《上市规则》及其他相关法律规定，未来将持续披露任何股份变动信息。公告由执行董事刘彦君签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.